Nuo Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Nuo Therapeutics, Inc. has filed its Q1 2024 10-Q report.</b>

AI Summary

Nuo Therapeutics, Inc. (AURX) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Nuo Therapeutics, Inc. filed a 10-Q for the period ending March 31, 2024. The company's principal business address is 8285 El Rio, Suite 150, Houston, TX 77054. Nuo Therapeutics, Inc. was formerly known as CYTOMEDIX INC and AUTOLOGOUS WOUND THERAPY INC. The company's fiscal year ends on December 31. The filing is for the period of 2024-01-01 to 2024-03-31.

Why It Matters

For investors and stakeholders tracking Nuo Therapeutics, Inc., this filing contains several important signals. This 10-Q filing provides an update on Nuo Therapeutics, Inc.'s financial performance and business operations for the first quarter of 2024. Understanding the details within this report is crucial for investors and stakeholders to assess the company's current financial health and strategic direction.

Risk Assessment

Risk Level: low — Nuo Therapeutics, Inc. shows low risk based on this filing. The filing is a standard quarterly report (10-Q) and does not contain immediate, significant financial or operational disclosures that would suggest a high-risk profile based solely on this document.

Analyst Insight

Review the detailed financial statements and management's discussion and analysis within the 10-Q to understand Nuo Therapeutics' Q1 2024 performance and outlook.

Key Numbers

• 2024-03-31 — Reporting Period End Date (10-Q filing)
• 2024-05-15 — Filing Date (10-Q filing)
• 001-32518 — SEC File Number (Nuo Therapeutics, Inc.)

Key Players & Entities

• Nuo Therapeutics, Inc. (company) — Filer name
• 8285 El Rio, Suite 150, Houston, TX 77054 (company) — Business address
• CYTOMEDIX INC (company) — Former company name
• AUTOLOGOUS WOUND THERAPY INC (company) — Former company name
• 2024-03-31 (date) — Conformed period of report
• 2024-05-15 (date) — Filed as of date

FAQ

Industry Context

Nuo Therapeutics, Inc. operates within the surgical and medical instruments & apparatus industry.

Regulatory Implications

The company is subject to standard SEC reporting requirements for public companies, including the filing of quarterly reports (10-Q).

What Investors Should Do

1. Analyze the financial statements for revenue, expenses, and net income for Q1 2024.
2. Review the Management's Discussion and Analysis (MD&A) section for insights into operational performance and future outlook.
3. Check for any new disclosures regarding business developments, risks, or legal proceedings.

Key Dates

• 2024-03-31: Quarterly Period End — End of the reporting period for the 10-Q filing.
• 2024-05-15: Filing Date — Date the 10-Q was officially filed with the SEC.

Year-Over-Year Comparison

This is the first 10-Q filing for the fiscal year 2024, providing an update from the previous year's filings.

Key Financial Figures

• $0.0001 — nding of the registrant's common stock, $0.0001 par value, was 44,241,516 . Table of C
• $250,000 — n excess of the FDIC insurance limit of $250,000 at March 31, 2024. We maintain our cash

Filing Documents

• aurx20240331_10q.htm (10-Q) — 546KB
• ex_669402.htm (EX-31) — 12KB
• ex_669403.htm (EX-32) — 5KB
• logo.jpg (GRAPHIC) — 5KB
• 0001437749-24-017125.txt (&nbsp;) — 3296KB
• aurx-20240331.xsd (EX-101.SCH) — 33KB
• aurx-20240331_cal.xml (EX-101.CAL) — 24KB
• aurx-20240331_def.xml (EX-101.DEF) — 216KB
• aurx-20240331_lab.xml (EX-101.LAB) — 210KB
• aurx-20240331_pre.xml (EX-101.PRE) — 238KB
• aurx20240331_10q_htm.xml (XML) — 425KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Unaudited Condensed Consolidated Financial Statements

Item 1. Unaudited Condensed Consolidated Financial Statements 1

Management ' s Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management ' s Discussion and Analysis of Financial Condition and Results of Operations 12

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 16

Controls and Procedures

Item 4. Controls and Procedures 16

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 18

Risk Factors

Item 1A. Risk Factors 18

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 18

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 18

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 18

Other Information

Item 5. Other Information 18

Exhibits

Item 6. Exhibits 19

Signatures

Signatures 20 Table of Contents PART I FINANCIAL INFORMATION

Condensed Consolidated Financial Statements

Item 1. Condensed Consolidated Financial Statements NUO THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS March 31, 2024 (unaudited) December 31, 2023 ASSETS Current assets Cash and cash equivalents $ 366,232 $ 928,681 Accounts receivable, net 229,769 250,703 Inventory, net 211,373 209,589 Prepaid expenses and other current assets 173,715 174,471 Total current assets 981,089 1,563,444 Property and equipment, net 41,315 45,082 Operating lease right of use assets 220,429 269,354 Total assets $ 1,242,833 $ 1,877,880 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 486,326 $ 394,518 Accrued expenses 214,651 188,622 Current portion of operating lease liabilities 60,299 91,387 Total current liabilities 761,276 674,527 Non-current portion of operating lease liabilities 148,109 164,205 Total liabilities 909,385 838,732 Commitments and contingencies (Note 6) Stockholders' equity Common stock; $ 0.0001 par value, 100,000,000 shares authorized, 44,241,516 shares issued and outstanding at March 31, 2024 and December 31, 2023 4,424 4,424 Additional paid-in capital 30,974,046 30,970,965 Accumulated deficit ( 30,645,022 ) ( 29,936,241 ) Total stockholders' equity 333,448 1,039,148 Total liabilities and stockholders' equity $ 1,242,833 $ 1,877,880 See accompanying notes to unaudited condensed consolidated financial statements. 1 Table of Contents NUO THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Three Months ended March 31, 2024 Three Months ended March 31, 2023 Revenue Product sales $ 234,577 $ 61,100 Total revenue 234,577 61,100 Costs of sales 50,591 10,419 Gross profit 183,986 50,681 Operating expenses Selling, general and administrative 893,232 905,874 Total operating expenses 893,232 905,874 Loss from operations ( 709,246 ) ( 855,193 ) Other income (

View Full Filing

View this 10-Q filing on SEC EDGAR